Completed PHASE3 INTERVENTIONAL NCT00073411

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression

Sponsor: Eli Lilly and Company

Interventions duloxetine escitalopram placebo

Updated 5 times since 2017 Last updated: Jul 30, 2007 Started: Nov 30, 2003 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Depression, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 5 data snapshots since 2003. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States